Table 1. Effects of resistant starch (RS) and placebo supplementation on AhR and NF-κB mRNA expression and IAA plasma values in chronic kidney disease patients on hemodialysis.
| Parameters | RS group (n=15) | Placebo group (n=16) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Post | p-value | Δ | Baseline | Post | p-value | Δ | p-value of Δ | |
| AhR expression | 1.1 ± 0.5 | 1.1 ± 0.5 | 0.84 | 0.3 (-0.4; 0.5) | 1.1 ± 0.5 | 1.0 ± 0.5 | 0.29 | -0.1 (-0.7; 0.3) | 0.19 |
| NF-κB expression | 1.35 ± 0.81 | 0.97 ± 0.37 | 0.06 | -0.2 (-0.6; 0.19) | 1.0 ± 0.54 | 1.16 ± 0.64 | 0.49 | 0.04 (-0.61; 0.61) | 0.18 |
| IAA (mg/L) | 2132.0 ± 1167.0 | 1917.0 ± 956.0 | 0.16 | 6.6 (-427.0; 226.0) | 2004.0 ± 1035.0 | 1840.0 ± 908.0 | 0.59 | -194.0 (-1254.0; 520.0) | 0.89 |
AhR, aryl hydrocarbon receptor; NF-κB, Nuclear factor-κB; IAA, indole-3-acetic acid. Data are presented as mean ± SD or median (25-75th percentile).